

RESEARCH OPPORTUNITY

NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. Determining which treatments are most effective requires research. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and Chief Program Officer Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials.

If you have questions about research at NAMI, please visit [NAMI.org/research](https://www.nami.org/research) or email us at research@nami.org.

WHAT IS THE STUDY?

This study is a clinical research trial for the oral medication BI 1358894. The trial will determine if BI 1358894 is safe and effective in patients with Major Depressive Disorder (MDD) who have not responded to other forms of treatment. Participants will be randomly assigned to receive a certain dose of BI 1358894, a placebo, or quetiapine for a period of six weeks. Quetiapine is a medication that has been approved for patients in the United States and the European Union who have not responded to first line treatment of MDD. Participants will receive compensation for their time and travel.

WHO CAN PARTICIPATE?

This study is seeking 431 participants. Participants may be eligible for this study if they:

- Are between the ages of 18 and 65
- Have been diagnosed with Major Depressive Disorder
- Have engaged in documented ongoing treatment for depression with one method for at least six weeks

Please note that these criteria are not complete. Certain other factors, including other mental health diagnoses, may disqualify an individual from participation. For a full list of inclusion and exclusion criteria, please visit [this site](#) for more information.

WHERE IS THE STUDY TAKING PLACE?

The study will take place at approximately 86 trial centers in 11 countries. Twenty of these trial centers are located in the United States. For a full list of study locations, please visit [this site](#).

HOW DO I LEARN MORE?

If you have questions or would like more information, please contact the researchers at (800) 236-4236 or register to learn more [here](#).